Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2025-12-25 @ 3:01 AM
NCT ID:
NCT06422533
Eligibility Criteria:
Inclusion Criteria:
* All patients \>18 years old
* Diagnosis of any hematological malignancy
* Severe neutropenia (polymorphonuclear \<500 cells/mm3)
* Fever (≥38.3 degrees Celsius in one measure, or ≥38 degrees Celsius in at least two measures)
* Median arterial pressure ≥65 mmHg on admission
* A life expectancy ≥ 5 days
* Agree to participate in the study
Exclusion Criteria:
* Known hypersensitivity to cephalosporins or anaphylaxis with beta-lactams
* Clinical signs related to hemodynamic instability
* Concomitant use of another antibiotic with activity against Gram-negatives (except Trimethoprim/Sulfamethoxazole (TMP/SMX) as prophylaxis for P. jirovecii
* Patients with end-stage chronic renal failure (\<10 ml/min by creatinine clearance-ACCr) or on renal replacement therapy.
* Patients with grade IV mucositis
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06422533
Study Brief:
Protocol Section:
NCT06422533